Risk factors for fracture among current, persistent users of bisphosphonates

E. S. LeBlanc, A. G. Rosales, A. Balasubramanian, C. D. O’Malley, O. Egbuna, Darin Friess, N. A. Perrin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Bisphosphonate therapy reduces but does not eliminate fracture occurrence. The incidence of fracture and risk factors for fractures among persistent, current users of bisphosphonates in a community setting have not been well studied.

Summary: Bisphosphonate therapy reduces fracture risk but does not eliminate fracture occurrence. We determined the fracture incidence and risk factors for fractures among 14,674 bisphosphonate users in a community setting. Bisphosphonate users remained at risk of fracture, and additional measures to prevent fractures in these patients would be beneficial.

Methods: We conducted a retrospective cohort study of 14,674 bisphosphonate users in a health maintenance organization. Patients were followed until a 3-month gap in therapy, creating a pool of highly compliant [mean medication possession ratio (MPR) of 94 %] current users. We used Cox proportional hazards models to identify risk factors for fractures among these persistent, current users.

Results: There were 867 fractures over the period of observation or 3.7 fractures per 100 users per year. Older patients who take multiple medications, have lower bone mineral density, have a history of prior fracture, and suffer from particular comorbidities (i.e., dementia, chronic kidney disease, and rheumatoid arthritis) are at higher risk of fracture while taking bisphosphonates.

Conclusion: Persistent, current bisphosphonate users remain at risk of fracture, and additional measures to prevent fractures in these patients would be of benefit.

Original languageEnglish (US)
Pages (from-to)713-725
Number of pages13
JournalOsteoporosis International
Volume26
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Diphosphonates
Health Maintenance Organizations
Incidence
Chronic Renal Insufficiency
Proportional Hazards Models
Bone Density
Dementia
Comorbidity
Rheumatoid Arthritis
Cohort Studies
Therapeutics
Retrospective Studies
Observation

Keywords

  • Bisphosphonates
  • Fractures
  • Osteoporosis
  • Risk factors

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

LeBlanc, E. S., Rosales, A. G., Balasubramanian, A., O’Malley, C. D., Egbuna, O., Friess, D., & Perrin, N. A. (2014). Risk factors for fracture among current, persistent users of bisphosphonates. Osteoporosis International, 26(2), 713-725. https://doi.org/10.1007/s00198-014-2941-9

Risk factors for fracture among current, persistent users of bisphosphonates. / LeBlanc, E. S.; Rosales, A. G.; Balasubramanian, A.; O’Malley, C. D.; Egbuna, O.; Friess, Darin; Perrin, N. A.

In: Osteoporosis International, Vol. 26, No. 2, 2014, p. 713-725.

Research output: Contribution to journalArticle

LeBlanc, ES, Rosales, AG, Balasubramanian, A, O’Malley, CD, Egbuna, O, Friess, D & Perrin, NA 2014, 'Risk factors for fracture among current, persistent users of bisphosphonates', Osteoporosis International, vol. 26, no. 2, pp. 713-725. https://doi.org/10.1007/s00198-014-2941-9
LeBlanc, E. S. ; Rosales, A. G. ; Balasubramanian, A. ; O’Malley, C. D. ; Egbuna, O. ; Friess, Darin ; Perrin, N. A. / Risk factors for fracture among current, persistent users of bisphosphonates. In: Osteoporosis International. 2014 ; Vol. 26, No. 2. pp. 713-725.
@article{16e6dcb7510848cfbc7a800a9c4729db,
title = "Risk factors for fracture among current, persistent users of bisphosphonates",
abstract = "Introduction: Bisphosphonate therapy reduces but does not eliminate fracture occurrence. The incidence of fracture and risk factors for fractures among persistent, current users of bisphosphonates in a community setting have not been well studied.Summary: Bisphosphonate therapy reduces fracture risk but does not eliminate fracture occurrence. We determined the fracture incidence and risk factors for fractures among 14,674 bisphosphonate users in a community setting. Bisphosphonate users remained at risk of fracture, and additional measures to prevent fractures in these patients would be beneficial.Methods: We conducted a retrospective cohort study of 14,674 bisphosphonate users in a health maintenance organization. Patients were followed until a 3-month gap in therapy, creating a pool of highly compliant [mean medication possession ratio (MPR) of 94 {\%}] current users. We used Cox proportional hazards models to identify risk factors for fractures among these persistent, current users.Results: There were 867 fractures over the period of observation or 3.7 fractures per 100 users per year. Older patients who take multiple medications, have lower bone mineral density, have a history of prior fracture, and suffer from particular comorbidities (i.e., dementia, chronic kidney disease, and rheumatoid arthritis) are at higher risk of fracture while taking bisphosphonates.Conclusion: Persistent, current bisphosphonate users remain at risk of fracture, and additional measures to prevent fractures in these patients would be of benefit.",
keywords = "Bisphosphonates, Fractures, Osteoporosis, Risk factors",
author = "LeBlanc, {E. S.} and Rosales, {A. G.} and A. Balasubramanian and O’Malley, {C. D.} and O. Egbuna and Darin Friess and Perrin, {N. A.}",
year = "2014",
doi = "10.1007/s00198-014-2941-9",
language = "English (US)",
volume = "26",
pages = "713--725",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "2",

}

TY - JOUR

T1 - Risk factors for fracture among current, persistent users of bisphosphonates

AU - LeBlanc, E. S.

AU - Rosales, A. G.

AU - Balasubramanian, A.

AU - O’Malley, C. D.

AU - Egbuna, O.

AU - Friess, Darin

AU - Perrin, N. A.

PY - 2014

Y1 - 2014

N2 - Introduction: Bisphosphonate therapy reduces but does not eliminate fracture occurrence. The incidence of fracture and risk factors for fractures among persistent, current users of bisphosphonates in a community setting have not been well studied.Summary: Bisphosphonate therapy reduces fracture risk but does not eliminate fracture occurrence. We determined the fracture incidence and risk factors for fractures among 14,674 bisphosphonate users in a community setting. Bisphosphonate users remained at risk of fracture, and additional measures to prevent fractures in these patients would be beneficial.Methods: We conducted a retrospective cohort study of 14,674 bisphosphonate users in a health maintenance organization. Patients were followed until a 3-month gap in therapy, creating a pool of highly compliant [mean medication possession ratio (MPR) of 94 %] current users. We used Cox proportional hazards models to identify risk factors for fractures among these persistent, current users.Results: There were 867 fractures over the period of observation or 3.7 fractures per 100 users per year. Older patients who take multiple medications, have lower bone mineral density, have a history of prior fracture, and suffer from particular comorbidities (i.e., dementia, chronic kidney disease, and rheumatoid arthritis) are at higher risk of fracture while taking bisphosphonates.Conclusion: Persistent, current bisphosphonate users remain at risk of fracture, and additional measures to prevent fractures in these patients would be of benefit.

AB - Introduction: Bisphosphonate therapy reduces but does not eliminate fracture occurrence. The incidence of fracture and risk factors for fractures among persistent, current users of bisphosphonates in a community setting have not been well studied.Summary: Bisphosphonate therapy reduces fracture risk but does not eliminate fracture occurrence. We determined the fracture incidence and risk factors for fractures among 14,674 bisphosphonate users in a community setting. Bisphosphonate users remained at risk of fracture, and additional measures to prevent fractures in these patients would be beneficial.Methods: We conducted a retrospective cohort study of 14,674 bisphosphonate users in a health maintenance organization. Patients were followed until a 3-month gap in therapy, creating a pool of highly compliant [mean medication possession ratio (MPR) of 94 %] current users. We used Cox proportional hazards models to identify risk factors for fractures among these persistent, current users.Results: There were 867 fractures over the period of observation or 3.7 fractures per 100 users per year. Older patients who take multiple medications, have lower bone mineral density, have a history of prior fracture, and suffer from particular comorbidities (i.e., dementia, chronic kidney disease, and rheumatoid arthritis) are at higher risk of fracture while taking bisphosphonates.Conclusion: Persistent, current bisphosphonate users remain at risk of fracture, and additional measures to prevent fractures in these patients would be of benefit.

KW - Bisphosphonates

KW - Fractures

KW - Osteoporosis

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84964222471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964222471&partnerID=8YFLogxK

U2 - 10.1007/s00198-014-2941-9

DO - 10.1007/s00198-014-2941-9

M3 - Article

C2 - 25354654

AN - SCOPUS:84964222471

VL - 26

SP - 713

EP - 725

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 2

ER -